AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34440175
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Trial: 34441840
Drug: Ciclesonide (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide (320 µg inhalation twice per day for 14 days)
Trial: 34442202
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (BLT) sessions of 10,000 lux for 30 minutes, Monday through Friday, for 4 weeks.
Trial: 34446044
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for colorectal cancer
Trial: 34446378
Drug: Impaired daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired daily functioning
Trial: 36116420
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg intravenously
Trial: 34452642
Drug: COPESS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPESS plus treatment as usual (TAU)
Trial: 34453241
Drug: Lurbinectedin and
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin and cisplatin combination with aprepitant (Group A)
Trial: 34453241
Drug: Lurbinectedin and
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin and cisplatin combination without aprepitant (Group B)
Trial: 34453622
Drug: Electrical impedance
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical impedance tomography (EIT) with saline bolus (10 ml 10% NaCl injection) during a respiratory hold
Trial: 34454047
Drug: Frameless unilateral
RxNorm normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frameless unilateral radiosurgical ablation of the thalamic ventral intermediate nucleus to a maximum dose of 160 Gy
Trial: 34454573
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) sessions, exercising at 30% of MIP, two daily sessions for 3 weeks.
Trial: 34454592
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care occupational therapy (OT)
Trial: 34454787
Drug: ACAM2000 smallpox
RxNorm normalized name: ACAM2000 Smallpox (Vaccinia) Live Vaccine Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACAM2000 smallpox vaccine
Trial: 34454787
Drug: Dryvax smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dryvax smallpox vaccine
Trial: 34455067
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort B)
Trial: 34455067
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort C)
Trial: 34457038
Drug: Oral masitinib
RxNorm normalized name: axitinib Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral masitinib (4.5 mg/kg/day)
Trial: 34458717
Drug: Injection port
RxNorm normalized name: Injection Port
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection port of ported PVCs
Trial: 38017564
Drug: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus vaccine
Trial: 34460083
Drug: NaIHS (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaIHS (50 mg ibuprofen, tid)
Trial: 34461561
Drug: High eicosapentaenoic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High eicosapentaenoic acid multinutrient supplement (1125 mg eicosapentaenoic acid, 441 mg docosahexaenoic acid, 330 mg magnesium, 7.5 mg vitamin E)
Trial: 34462007
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion 1-2 μg/kg/min for 48 hours
Trial: 34462189
Drug: GLS-010 (zimberelimab)
RxNorm normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-010 (zimberelimab) 240 mg, intravenous, once every 2 weeks until progression, death, unacceptable toxicity, or consent withdrawal
Trial: 34462238
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone withdrawal
Trial: 34462732
Drug: icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: icosapent ethyl (8 g daily for 3 days followed by 4 g daily for 11 days)
Trial: 35921817
Drug: CD24Fc treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD24Fc treatment
Trial: 34463835
Drug: Therapeutic exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercise (TE) intervention, delivered twice a week for 3 months, consisting of 1 hour of TE and 30 minutes of nutritional education
Trial: 34464523
Drug: Equine-Assisted Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine-Assisted Therapy
Trial: 34465452
Drug: Prolonged cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged cyclical treatment regimen of dydrogesterone 10 mg 2 or 3 times daily between the 5th and 25th days of the menstrual cycle
Trial: 34465452
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment regimen of dydrogesterone 10 mg 2 or 3 times daily
Trial: 34465452
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimens (prolonged cyclical and continuous)
Trial: 34465599
Drug: LY3300054/anti-TIM-3 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3300054/anti-TIM-3 combination
Trial: 34466766
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of immunotherapy, surgery, external beam radiation
Trial: 34467254
Drug: Etrolizumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab treatment
Trial: 34467476
Drug: gBRCA1/2 mutations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gBRCA1/2 mutations in hormone receptor-positive MBC
Trial: 34468953
Drug: Concurrent meningitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent meningitis and extra-cerebral IPD
Trial: 34468953
Drug: Non-vaccine serotypes
RxNorm normalized name: SARS-COV-2 (COVID-19) vaccine, vector non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vaccine serotypes
Trial: 34468963
Drug: Antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal therapy (voriconazole alone or sequential/combined therapy)
Trial: 34468963
Drug: Antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal therapy (voriconazole)
Trial: 34468963
Drug: Optimal voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimal voriconazole regimen (loading dose, 200 mg twice daily; daily maintenance dose, 100 mg)
Trial: 34469268
Drug: Treatments over
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments over time
Trial: 34470049
Drug: Venetoclax 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 800 mg, Carfilzomib 70 mg/m2, Dexamethasone 40 mg
Trial: 34470049
Drug: Venetoclax 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 400 or 800 mg, Carfilzomib 27, 56, or 70 mg/m2, Dexamethasone 20 or 40 mg
Trial: 34470489
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) with complete recanalization
Trial: 34470614
Drug: Optimal BMI
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal BMI status and consistent multivitamin supplement intake
Trial: 34472719
Drug: Anthracycline-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based chemotherapy (ABC)
Trial: 34472769
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention program combined with oral antioxidant therapy (multivitamins, coenzyme Q10, omega-3, and oligo-elements) for 3 months
Trial: 34473227
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) methods for classification of olfactory dysfunction
Trial: 34473594
Drug: VARIVAX™ (Varicella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VARIVAX™ (Varicella Virus Vaccine Live [Oka/Merck]) 0.5 mL, 2 doses 6 weeks apart
Trial: 34474584
Drug: Thin-Strut Drug-Eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin-Strut Drug-Eluting Stents (DES)
Trial: 34474927
Drug: AVB-500 +
RxNorm normalized name: AVB-S6-500
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB-500 + PAC (subgroup with no prior bevacizumab or AVB-500 trough levels >13.8 mg/L)
Trial: 34475750
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) intravitreal implant 700 µg
Trial: 34476122
Drug: Acute medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute medication overuse (AMO)
Trial: 34476122
Drug: Simple analgesics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple analgesics, combination analgesics, and opioids
Trial: 34476229
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health (mHealth) intervention, details on dosage and duration not available
Trial: 34476411
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of effusion and haemarthrosis
Trial: 34476623
Drug: Therapist-report measure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-report measure of family therapy techniques (ITT-CEFT)
Trial: 34477937
Drug: fedratinib 600
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fedratinib 600 mg
Trial: 34477937
Drug: cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cocktail of digoxin 0.25 mg, rosuvastatin 10 mg, and metformin 1000 mg
Trial: 34477993
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy (adalimumab, etanercept)
Trial: 34478460
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated cholera vaccine
Trial: 34478486
Drug: Gut microbial-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut microbial-derived indole compounds
Trial: 34478487
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (SCHOLAR-1)
Trial: 34478825
Drug: Time Restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time Restricted Feeding (TRF) - 4-6 hours eating window, 18-20 hours fasting window daily
Trial: 34479362
Drug: 75-g glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-g glucose drink (OG)
Trial: 34479925
Drug: MVA-BN-brachyury-TRICOM vaccine
RxNorm normalized name: MVA-BN-brachyury-TRICOM vaccine
DrugBank: MVA-BN-brachyury-TRICOM vaccine (DB17424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-brachyury-TRICOM vaccine administered intravenously at three dose levels on days 1, 22, and 43.
Trial: 34479925
Drug: MVA-BN-brachyury-TRICOM vaccine
RxNorm normalized name: MVA-BN-brachyury-TRICOM vaccine
DrugBank: MVA-BN-brachyury-TRICOM vaccine (DB17424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-brachyury-TRICOM vaccine
Trial: 34482353
Drug: Latency reversal
RxNorm normalized name: edrophonium chloride Injectable Solution [Reversol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latency reversal agents (LRA) - HDAC inhibitor
Trial: 34483270
Drug: Topical insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical insulin (1 unit per mL), applied 4 times per day until resolution of persistent epithelial defect (PED) or ulcer.
Trial: 34484101
Drug: Botulinum Toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum Toxin-A treatment, dosage and duration not specified
Trial: 34484187
Drug: iNeo-Vac-P01, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine
Trial: 34484431
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg orally each day continuously until unacceptable toxicity or tumor progression
Trial: 34484473
Drug: Durvalumab after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab after concurrent chemoradiotherapy
Trial: 34484473
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after concurrent chemoradiotherapy
Trial: 34484473
Drug: Durvalumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab with subsequent immunotherapy removed
Trial: 34484473
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with subsequent immunotherapy removed
Trial: 34484887
Drug: Wait list/treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait list/treatment as usual (WL/TAU)
Trial: 34485882
Drug: Locoregional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapies (LRT) before liver transplantation (LT)
Trial: 34487283
Drug: Optimal administered
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal administered radioactivity
Trial: 34488662
Drug: Selinexor with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor with low dose dexamethasone
Trial: 34489309
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment with RAS/BRAF mutation analysis
Trial: 34490414
Drug: B cell
RxNorm normalized name: B cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell depleting therapies (BCDTs)
Trial: 34490590
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with ticagrelor or prasugrel
Trial: 34490604
Drug: Sodium restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium restriction (2 g of sodium/day)
Trial: 34490604
Drug: Sodium restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium restriction (2 g of sodium/day) with sodium intake < 2500 mg/day
Trial: 34490604
Drug: Control (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (3 g of sodium/day)
Trial: 34491661
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood-pressure target of 110 to less than 130 mm Hg)
Trial: 34491661
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic blood-pressure target of 130 to less than 150 mm Hg)
Trial: 34491815
Drug: Cabozantinib 40
RxNorm normalized name: cabozantinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 40 mg once a day plus atezolizumab 1,200 mg intravenously every 3 weeks
Trial: 34491815
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg once a day plus atezolizumab 1,200 mg intravenously every 3 weeks
Trial: 34491815
Drug: Cabozantinib (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (dosage not specified) plus atezolizumab 1,200 mg intravenously every 3 weeks in non-clear cell RCC
Trial: 34492682
Drug: Dasatinib-dexamethasone induction
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib-dexamethasone induction followed by chemotherapy
Trial: 34492703
Drug: CD19CAR T-cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19CAR T-cell therapy
Trial: 34493347
Drug: Initial sUA
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial sUA < 6.0 mg/dL
Trial: 34493347
Drug: Initial sUA
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial sUA between 6.0-6.8 mg/dL
Trial: 34496148
Drug: Issuing 2-3
RxNorm normalized name: ALCOHOL 0.75 TOPICAL CLOTH [Care plus issue]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Issuing 2-3 months of pills at a time
Trial: 34496270
Drug: Facial botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facial botulinum toxin injections
Trial: 34496270
Drug: Cervical botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical botulinum toxin injections
Trial: 34496904
Drug: TKA implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKA implants
Trial: 34499038
Drug: Digital rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rehabilitation therapy using a biofeedback device provided by SWORD Health, performed independently at home.
Trial: 34499416
Drug: Merestinib 80
RxNorm normalized name: Mereletinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Merestinib 80 mg orally QD during a 28-day cycle
Trial: 34499416
Drug: Merestinib 120
RxNorm normalized name: Mereletinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Merestinib 120 mg orally QD during a 28-day cycle
Trial: 34499416
Drug: Merestinib 80
RxNorm normalized name: Mereletinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Merestinib 80 mg orally QD with cisplatin 25 mg/m2
Trial: 34499613
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioral therapy, mindfulness meditation, and yoga (CBT-MY)
Trial: 34499720
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefazolin IV infusion
Trial: 34499720
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefazolin IV infusion (administered if delivery delayed >8 h)
Trial: 34499720
Drug: Standard pre-delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pre-delivery maternal cefazolin dosing
Trial: 34503455
Drug: Propofol continuous
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol continuous infusion with a stepwise increase of 1 μg/mL in effect-site concentration (C)
Trial: 34503957
Drug: Glucagonlike peptide-1
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagonlike peptide-1 receptor (GLP1R) imaging using PET radioligand
Trial: 34504096
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel and bevacizumab chemotherapy
Trial: 34504096
Drug: CTCs and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTCs and ctDNA levels at baseline and after four weeks of treatment
Trial: 34504096
Drug: CTC count
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTC count at four weeks (≥5CTC/7.5 mL)
Trial: 34505132
Drug: Tuberculosis Preventive
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculosis Preventive Therapy
Trial: 34505172
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose (RD) protocol, volumetric CT dose index (CTDIvol) 3.04 mGy, 64-slice unit
Trial: 34505172
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose (ULD) protocol, median CTDIvol 0.38 mGy, dual-source unit
Trial: 34506875
Drug: Fluid bolus
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid bolus of 500 ml plasma-lyte A
Trial: 34507560
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with a stoma
Trial: 34507560
Drug: No stoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stoma treatment